| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $11,661,303 | 31 | 100 |
| Lin Elizabeth Yeu | Chief Medical Officer | 0 | $0 | 2 | $206,527 | $-206,527 |
| Neervannan Seshadri | Chief Operating Officer | 0 | $0 | 3 | $363,142 | $-363,142 |
| Wahl Bryan | General Counsel | 0 | $0 | 3 | $463,766 | $-463,766 |
| Farrow Jeffrey S | See Remarks | 0 | $0 | 4 | $728,342 | $-728,342 |
| Mottiwala Aziz | Chief Commercial Officer | 0 | $0 | 4 | $1.27M | $-1.27M |
| Azamian Bobak R. | President/CEO and Board Chair | 0 | $0 | 7 | $2.59M | $-2.59M |
| Whitfield Dianne C. | Chief Human Resources Officer | 0 | $0 | 6 | $2.63M | $-2.63M |
| LINK WILLIAM J PHD | director | 0 | $0 | 2 | $3.41M | $-3.41M |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Over the last 12 months, insiders at Tarsus Pharmaceuticals, Inc. have bought $0 and sold $11.66M worth of Tarsus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Tarsus Pharmaceuticals, Inc. have bought $1.59M and sold $14.95M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $18,960 was made by Goldberg Andrew D. (director) on 2023‑12‑15.
| 2026-01-02 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 5,715 0.0132% | $80.09 | $457,714 | -5.53% | |
| 2026-01-02 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 15,565 0.0361% | $80.67 | $1.26M | -5.53% | |
| 2025-12-24 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 6,000 0.0141% | $82.51 | $495,089 | -2.40% | |
| 2025-12-16 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 7,397 0.0178% | $80.10 | $592,500 | -0.13% | |
| 2025-12-16 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 2,078 0.005% | $79.50 | $165,201 | -0.13% | |
| 2025-12-15 | Sale | LINK WILLIAM J PHD | director | 22,946 0.0546% | $81.26 | $1.86M | -2.07% | |
| 2025-09-24 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 6,000 0.0142% | $55.37 | $332,220 | +35.97% | |
| 2025-09-08 | Sale | LINK WILLIAM J PHD | director | 27,116 0.0644% | $57.00 | $1.55M | +28.19% | |
| 2025-08-11 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 6,000 0.0142% | $50.00 | $300,000 | +40.28% | |
| 2025-06-17 | Sale | Farrow Jeffrey S | See Remarks | 13,608 0.0332% | $40.42 | $550,035 | +50.76% | |
| 2025-06-16 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 1,006 0.0024% | $41.08 | $41,326 | +43.23% | |
| 2025-06-09 | Sale | Mottiwala Aziz | Chief Commercial Officer | 17,500 0.0423% | $43.76 | $765,800 | +35.91% | |
| 2025-03-24 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 6,000 0.0138% | $50.00 | $300,000 | +1.62% | |
| 2025-03-20 | Sale | Neervannan Seshadri | Chief Operating Officer | 2,435 0.0059% | $50.11 | $122,018 | +5.27% | |
| 2025-03-20 | Sale | Mottiwala Aziz | Chief Commercial Officer | 3,365 0.0082% | $50.11 | $168,620 | +5.27% | |
| 2025-03-20 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 8,534 0.0208% | $50.11 | $427,639 | +5.27% | |
| 2025-03-20 | Sale | Wahl Bryan | General Counsel | 3,084 0.0075% | $50.11 | $154,539 | +5.27% | |
| 2025-03-20 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 2,137 0.0052% | $50.11 | $107,085 | +5.27% | |
| 2025-03-20 | Sale | Farrow Jeffrey S | See Remarks | 1,186 0.0029% | $50.11 | $59,430 | +5.27% | |
| 2025-03-19 | Sale | Neervannan Seshadri | Chief Operating Officer | 2,543 0.0059% | $47.40 | $120,538 | +5.67% |
| Azamian Bobak R. | President/CEO and Board Chair | 857991 2.0212% | $61.04M | 0 | 63 | |
| Neervannan Seshadri | Chief Operating Officer | 79682 0.1877% | $5.67M | 0 | 10 | |
| Wahl Bryan | General Counsel | 51712 0.1218% | $3.68M | 0 | 14 | |
| Mottiwala Aziz | Chief Commercial Officer | 47557 0.112% | $3.38M | 0 | 21 | |
| Farrow Jeffrey S | See Remarks | 36704 0.0865% | $2.61M | 0 | 5 | |
| Whitfield Dianne C. | Chief Human Resources Officer | 23393 0.0551% | $1.66M | 0 | 17 | |
| Lin Elizabeth Yeu | Chief Medical Officer | 21941 0.0517% | $1.56M | 2 | 2 | +27.05% |
| LINK WILLIAM J PHD | director | 0 0% | $0 | 0 | 3 | |
| Vivo Capital Fund IX, L.P. | 2469001 5.8164% | $175.64M | 0 | 2 | ||
| Vivo Capital IX, LLC | 10 percent owner | 2469001 5.8164% | $175.64M | 1 | 10 | +36.85% |
| RTW INVESTMENTS, LP | 10 percent owner | 2013601 4.7436% | $143.25M | 0 | 1 | |
| Tester Jason E. | 1920933 4.5253% | $136.66M | 1 | 0 | +36.85% | |
| Horowitz Limited Partnership VIII | 10 percent owner | 1920933 4.5253% | $136.66M | 1 | 0 | +36.85% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 1917157 4.5164% | $136.39M | 1 | 0 | +36.85% |
| Ackermann Michael | 100000 0.2356% | $7.11M | 1 | 9 | +25.23% | |
| Greenstein Leonard M. | Chief Financial Officer | 26785 0.0631% | $1.91M | 0 | 14 | |
| Holdbrook Mark J. | V.P., Clinical Affairs | 3191 0.0075% | $227,007.74 | 0 | 3 | |
| Goldberg Andrew D. | director | 3000 0.0071% | $213,420.00 | 1 | 0 | +69.5% |
| Trevejo Jose M. | CHIEF MEDICAL OFFICER | 2251 0.0053% | $160,136.14 | 0 | 8 |
$159,914,414 | 243 | 18.52% | $3.65B | |
$11,588,217 | 69 | 42.07% | $2.79B | |
$104,428,685 | 44 | 22.55% | $3.24B | |
$148,770,544 | 34 | 80.63% | $3.26B | |
$5,066,938 | 27 | 26.38% | $3.09B | |
$150,253,463 | 26 | -52.83% | $2.98B | |
$61,703,557 | 26 | 40.25% | $3.3B | |
$27,105,902 | 21 | -16.06% | $2.73B | |
$137,061,250 | 16 | 23.01% | $3.17B | |
$73,814,940 | 15 | -4.77% | $2.7B | |
$92,580,864 | 14 | -1.28% | $2.9B | |
$1,248,715 | 10 | 5.66% | $3.29B | |
$45,445,266 | 9 | -24.96% | $3.14B | |
Tarsus Pharmaceuticals, Inc. (TARS) | $32,575,266 | 8 | 37.03% | $3.02B |
$91,589,325 | 7 | -6.97% | $2.7B | |
$461,215 | 5 | 10.35% | $3.59B | |
$24,000,085 | 4 | 33.26% | $2.68B | |
$142,493,653 | 3 | 4.30% | $2.89B | |
$9,900,000 | 1 | -7.19% | $2.81B |
| Increased Positions | 104 | +40.31% | 5M | +10.22% |
| Decreased Positions | 117 | -45.35% | 5M | -11.49% |
| New Positions | 36 | New | 2M | New |
| Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
| Total Postitions | 245 | -5.04% | 45M | -1.27% |
| Blackrock, Inc. | $305,280.00 | 9% | 3.78M | -12,564 | -0.33% | 2025-09-30 |
| Rtw Investments, Lp | $256,642.00 | 7.57% | 3.18M | +65,756 | +2.11% | 2025-09-30 |
| Deep Track Capital, Lp | $242,310.00 | 7.14% | 3M | +1M | +71.43% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $215,308.00 | 6.35% | 2.67M | -310,401 | -10.43% | 2025-09-30 |
| Jennison Associates Llc | $210,372.00 | 6.2% | 2.6M | +136,582 | +5.53% | 2025-09-30 |
| Tang Capital Management Llc | $198,274.00 | 5.85% | 2.45M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $183,517.00 | 5.41% | 2.27M | -25,264 | -1.1% | 2025-09-30 |
| Morgan Stanley | $154,465.00 | 4.55% | 1.91M | -143,316 | -6.97% | 2025-09-30 |
| Janus Henderson Group Plc | $116,228.00 | 3.43% | 1.44M | -367,948 | -20.36% | 2025-09-30 |
| Assenagon Asset Management S.A. | $100,797.00 | 2.97% | 1.25M | +250,367 | +25.1% | 2025-09-30 |